CELCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Celcuity Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$57.12+0.54 (+0.95%)
Close on Oct 19, 2026
- Market cap
- $3.13B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -62.3% | -61.1% | -163.8% | |
| Return on assets | – | -57.0% | -49.8% | |
| Current ratio | 13.27 | 10.26 | 10.55 | |
| Debt to equity | – | 0.00 | 1.26 | |
| Interest coverage | – | -79634.7× | -10.0× | |
| Diluted shares | 6M | 10M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Celcuity generated $346.88M from operations and spent $837.31K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$346.88M
Used
$837.31K
Capital expenditure$837.31K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$177.04M
- Cash generatingOperating cash flow above zero-$153.28M
- Return on assets improvedROA up on the prior year-58.5% → -72.2%
- Earnings backed by cashOperating cash flow above net income-$153.28M vs -$177.04M
- Less leverageLong-term debt to assets fell39.9% → 27.1%
- Better liquidityCurrent ratio rose7.71 → 10.55
- No dilutionShare count did not rise39M → 47M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –